Streamlining Hematology Denial Management with Klivira

Effective hematology denial management is critical for clinics and health systems to ensure financial stability and uninterrupted patient access to high-cost, life-sustaining therapies.

The complexity of hematologic conditions, coupled with the high cost and stringent prior authorization requirements for specialty drugs and advanced treatments, makes hematology a high-risk area for claim denials. Manual denial workflows lead to significant administrative burden, delayed revenue, and potential care disruptions. Klivira automates the denial management lifecycle, transforming a reactive process into a proactive strategy.

The Unique Challenges of Hematology Denials

Hematology prior authorizations frequently involve complex, high-cost therapies such as CAR-T cell therapies (e.g., Yescarta, Kymriah) for hematologic oncology, hemophilia factor concentrates (e.g., Advate, Hemlibra), and specialty drugs for sickle cell disease (e.g., Oxbryta, Adakveo). Denials in this specialty often stem from specific clinical criteria, documentation gaps, or payer policy variations for novel agents, directly impacting patient access and revenue integrity.

Common Denial Triggers in Hematology

**CAR-T Cell Therapies**: Eligibility documentation gaps, prior-line therapy adherence per NCCN guidelines, or specific diagnosis confirmation requirements are frequent denial points.
**Hemophilia Factor Concentrates**: Denials often arise from criteria discrepancies between prophylaxis and on-demand treatment, or insufficient documentation of factor levels, joint health, and bleeding episodes.
**Sickle Cell Specialty Drugs**: Payer-specific medical necessity criteria for drugs like voxelotor or crizanlizumab can lead to denials if not meticulously documented.
**Hematologic Oncology**: Gaps in NCCN-compendium support for novel agents, or insufficient evidence for off-label use in lymphomas, leukemias, or multiple myeloma.

Klivira's Automated Approach to Hematology Denial Management

Klivira's platform is engineered to address the specific nuances of hematology denials. We leverage ASH and NCCN-aware policy logic, automate the tracking of hemophilia factor utilization, and streamline CAR-T eligibility documentation. By normalizing X12 CARC/RARC codes and payer-specific denial reasons, Klivira ensures accurate categorization and routing of hematology-related denials from all intake channels, including X12 835, X12 277, and Da Vinci PAS `ClaimResponse`.

Automating the Hematology Appeal Workflow

**Intelligent Routing**: Denials are automatically triaged to claim correction, appeal, or peer-to-peer pathways based on normalized reason codes and payer-specific policies.
**FHIR-Enabled Documentation**: Klivira pulls relevant clinical documentation from your EMR via FHIR (e.g., updated lab results, problem lists, physician notes) to assemble robust appeal packets.
**Timely Filing Enforcement**: Proactive tracking and alerts ensure that appeal windows are never missed, a critical safeguard for high-value hematology claims.
**Payer-Specific Appeal Submission**: Appeals are submitted via the payer's preferred channel, whether portal API or fax, adhering to specific appeal-level requirements.
**Pattern Detection**: Klivira identifies recurring denial patterns by payer or specific hematologic therapy, feeding back insights to improve upstream PA submission accuracy and reduce future denials.

Integrating with Your EMR and Payer Ecosystem

Seamless integration is paramount for effective denial management. Klivira connects with your EMR to extract the detailed clinical evidence required for hematology appeals and writes back appeal outcomes, ensuring a single source of truth for your revenue cycle and clinical teams. Our system also interfaces directly with payer portals and utilizes industry standards like X12 835 and X12 277 for comprehensive denial intake and status tracking, minimizing manual intervention across the entire prior authorization and denial lifecycle.

Frequently asked questions

How does Klivira handle denials for CAR-T cell therapies in hematology?

Klivira automates the assembly of appeal packets for CAR-T therapy denials by pulling critical documentation like diagnosis confirmations and prior-line therapy details from your EMR via FHIR. Our system applies NCCN-aware policy logic to ensure appeals address specific eligibility and medical necessity criteria, reducing rework for these high-value treatments.

What are the most common denial reasons Klivira addresses for hemophilia factor concentrates?

For hemophilia factor concentrates, Klivira specifically addresses denials related to prophylaxis-vs-on-demand criteria and documentation gaps concerning factor levels, joint health, or bleeding episodes. Our system helps ensure that appeals are supported by the necessary clinical evidence, aligning with ASH guidelines.

Can Klivira integrate with our existing EMR to retrieve documentation for hematology denial appeals?

Yes, Klivira integrates with your EMR using FHIR standards to automatically retrieve relevant clinical documentation, such as updated lab results, imaging reports, and physician notes. This capability ensures that your hematology appeal packets are comprehensive and clinically robust without manual chart review.

How does Klivira help prevent timely filing breaches for hematology appeals?

Klivira enforces timely filing windows by tracking appeal deadlines per payer and proactively alerting your team to upcoming due dates. This automated monitoring prevents appeals for high-cost hematology treatments from being abandoned due to missed submission windows, safeguarding your revenue.

Does Klivira provide insights into recurring hematology denial patterns?

Absolutely. Klivira's reporting and pattern detection capabilities analyze denial reasons by payer, specific hematologic therapy, and provider. This feedback loop helps identify systemic issues and informs adjustments to your upstream prior authorization submission processes, ultimately reducing future denials in hematology.